A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda

  1. François Blanquart  Is a corresponding author
  2. Mary Kate Grabowski
  3. Joshua Herbeck
  4. Fred Nalugoda
  5. David Serwadda
  6. Michael A Eller
  7. Merlin L Robb
  8. Ronald Gray
  9. Godfrey Kigozi
  10. Oliver Laeyendecker
  11. Katrina A Lythgoe
  12. Gertrude Nakigozi
  13. Thomas C Quinn
  14. Steven J Reynolds
  15. Maria J Wawer
  16. Christophe Fraser
  1. Imperial College London, United Kingdom
  2. Johns Hopkins University, United States
  3. University of Washington, United States
  4. Rakai Health Sciences Program, Uganda
  5. Walter Reed Army Institute of Research, United States
  6. National Institutes of Health, United States

Abstract

Evolutionary theory hypothesizes that intermediate virulence maximizes pathogen fitness as a result of a trade-off between virulence and transmission, but empirical evidence remains scarce. We bridge this gap using data from a large and long-standing HIV-1 prospective cohort, in Uganda. We use an epidemiological-evolutionary model parameterised with this data to derive evolutionary predictions based on analysis and detailed individual-based simulations. We robustly predict stabilising selection towards a low level of virulence, and rapid attenuation of the virus. Accordingly, set-point viral load, the most common measure of virulence, has declined in the last 20 years. Our model also predicts that subtype A is slowly outcompeting subtype D, with both subtypes becoming less virulent, as observed in the data. Reduction of set-point viral loads should have resulted in a 20% reduction in incidence, and a three years extension of untreated asymptomatic infection, increasing opportunities for timely treatment of infected individuals.

Data availability

The following data sets were generated

Article and author information

Author details

  1. François Blanquart

    MRC Centre for Outbreak Analysis and Modelling, School of Public Health, Imperial College London, London, United Kingdom
    For correspondence
    f.blanquart@imperial.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0591-2466
  2. Mary Kate Grabowski

    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Joshua Herbeck

    International Clinical Research Center, University of Washington, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4577-7406
  4. Fred Nalugoda

    Rakai Health Sciences Program, Entebbe, Uganda
    Competing interests
    The authors declare that no competing interests exist.
  5. David Serwadda

    Rakai Health Sciences Program, Entebbe, Uganda
    Competing interests
    The authors declare that no competing interests exist.
  6. Michael A Eller

    U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Merlin L Robb

    U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Ronald Gray

    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Godfrey Kigozi

    Rakai Health Sciences Program, Entebbe, Uganda
    Competing interests
    The authors declare that no competing interests exist.
  10. Oliver Laeyendecker

    Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Katrina A Lythgoe

    MRC Centre for Outbreak Analysis and Modelling, School of Public Health, Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Gertrude Nakigozi

    Rakai Health Sciences Program, Entebbe, Uganda
    Competing interests
    The authors declare that no competing interests exist.
  13. Thomas C Quinn

    Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Steven J Reynolds

    Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Maria J Wawer

    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Christophe Fraser

    MRC Centre for Outbreak Analysis and Modelling, School of Public Health, Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.

Funding

European Commission (Intra European Fellowship 657768)

  • François Blanquart

World Bank Group

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

Henry M. Jackson Foundation (W81XWH-07-2-0067)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

U.S. Department of Defense (W81XWH-07-2-0067)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

National Institutes of Health (R01AI108490; P30AI027757)

  • Joshua Herbeck

European Research Council (PBDR-339251)

  • Christophe Fraser

National Institute of Allergy and Infectious Diseases (R01 Al 29314; R01 AI34826; UO1 AI11171-01-02)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

National Institute of Child Health and Human Development (5P30 HD 06268)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

John E. Fogarty Foundation for Persons with Intellectual and Developmental Disabilities (5D43TW00010)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

John Snow Inc. (5024-30)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

Pfizer (5024-30)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

Rockefeller Foundation

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Informed consent was obtained from all the participants in the Rakai Community Cohort Study.The Scientific and Ethics Committee of the Uganda Virus Research Institute (UVRI) of the Ministry of Health provides the Institutional Review Board approval and monitoring of all Rakai research.

Copyright

© 2016, Blanquart et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,798
    views
  • 661
    downloads
  • 45
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. François Blanquart
  2. Mary Kate Grabowski
  3. Joshua Herbeck
  4. Fred Nalugoda
  5. David Serwadda
  6. Michael A Eller
  7. Merlin L Robb
  8. Ronald Gray
  9. Godfrey Kigozi
  10. Oliver Laeyendecker
  11. Katrina A Lythgoe
  12. Gertrude Nakigozi
  13. Thomas C Quinn
  14. Steven J Reynolds
  15. Maria J Wawer
  16. Christophe Fraser
(2016)
A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda
eLife 5:e20492.
https://doi.org/10.7554/eLife.20492

Share this article

https://doi.org/10.7554/eLife.20492

Further reading

    1. Epidemiology and Global Health
    Xiaoning Wang, Jinxiang Zhao ... Dong Liu
    Research Article

    Artificially sweetened beverages containing noncaloric monosaccharides were suggested as healthier alternatives to sugar-sweetened beverages. Nevertheless, the potential detrimental effects of these noncaloric monosaccharides on blood vessel function remain inadequately understood. We have established a zebrafish model that exhibits significant excessive angiogenesis induced by high glucose, resembling the hyperangiogenic characteristics observed in proliferative diabetic retinopathy (PDR). Utilizing this model, we observed that glucose and noncaloric monosaccharides could induce excessive formation of blood vessels, especially intersegmental vessels (ISVs). The excessively branched vessels were observed to be formed by ectopic activation of quiescent endothelial cells (ECs) into tip cells. Single-cell transcriptomic sequencing analysis of the ECs in the embryos exposed to high glucose revealed an augmented ratio of capillary ECs, proliferating ECs, and a series of upregulated proangiogenic genes. Further analysis and experiments validated that reduced foxo1a mediated the excessive angiogenesis induced by monosaccharides via upregulating the expression of marcksl1a. This study has provided new evidence showing the negative effects of noncaloric monosaccharides on the vascular system and the underlying mechanisms.

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Amanda C Perofsky, John Huddleston ... Cécile Viboud
    Research Article

    Influenza viruses continually evolve new antigenic variants, through mutations in epitopes of their major surface proteins, hemagglutinin (HA) and neuraminidase (NA). Antigenic drift potentiates the reinfection of previously infected individuals, but the contribution of this process to variability in annual epidemics is not well understood. Here, we link influenza A(H3N2) virus evolution to regional epidemic dynamics in the United States during 1997—2019. We integrate phenotypic measures of HA antigenic drift and sequence-based measures of HA and NA fitness to infer antigenic and genetic distances between viruses circulating in successive seasons. We estimate the magnitude, severity, timing, transmission rate, age-specific patterns, and subtype dominance of each regional outbreak and find that genetic distance based on broad sets of epitope sites is the strongest evolutionary predictor of A(H3N2) virus epidemiology. Increased HA and NA epitope distance between seasons correlates with larger, more intense epidemics, higher transmission, greater A(H3N2) subtype dominance, and a greater proportion of cases in adults relative to children, consistent with increased population susceptibility. Based on random forest models, A(H1N1) incidence impacts A(H3N2) epidemics to a greater extent than viral evolution, suggesting that subtype interference is a major driver of influenza A virus infection ynamics, presumably via heterosubtypic cross-immunity.